Webinar Summary – Building the Intelligent Pharma Enterprise

Automation Unplugged · Episode 4 · A recap for those who couldn’t attend

For the fourth episode of Automation Unplugged India Automation Hub’s series of candid, practitioner-led conversations about what is actually happening on the ground in Indian industry we narrowed the lens to pharma. The question at the center of the session: what happens when India stops being a manufacturing back office and starts running the intelligent enterprise?

Our guest was Dr. Girish Basavaraju, who brings more than two decades across the pharmaceutical value chain R&D, engineering, safety, technology transfer, manufacturing and quality as a Six Sigma Black Belt and a leader of cross-functional teams and digital transformation programs. He now drives global business operations from India for Cosette Pharmaceuticals, a US pharmaceutical company. What followed was a frank read on GCCs, talent, AI, regulation and cybersecurity.

From cost center to innovation hub

The Global Capability Center has been fundamentally redefined. What began around 2007 Pfizer’s Chennai operation, measured largely on efficiency and cost savings, has matured into a strategic partner to its US and European counterparts. Today’s GCCs run commercial and data analytics, manufacturing excellence, supply-chain planning, clinical data management and, increasingly, AI development and data engineering. Some now lead global functions rather than merely support them.

Dr. Basavaraju credited three durable strengths that set India apart: deep scientific talent, digital capability built over two decades of IT and IT-enabled services, and execution excellence. The scale is striking by one media count he cited, 197 GCCs were established in Hyderabad alone over roughly 2.5 years, with companies such as Amgen, Johnson & Johnson, Novartis and Pfizer scaling their India operations past 1,000 people. His verdict: these are no longer back offices or shared services, but global innovation and transformation hubs.

COVID accelerated the story; it didn’t start it

The pandemic, he argued, is best understood as an accelerator rather than an origin. Investment in automation and shared services was already underway; COVID simply compressed five-to-ten years of GCC growth into 18–24 months. It also exposed how easily global supply chains could be disrupted, pushing diversification and risk mitigation to the top of the strategic agenda even as Indian companies delivered vaccines at scale across globally connected systems.

The new risk map

As more responsibility concentrates in India, Dr. Basavaraju flagged this as an opportunity for leadership rather than a weakness but one with clear watch-items. Chief among them: concentration risk (no company wants every asset on one site), talent (the challenge is retaining and training, not headcount), consistent quality as operations scale, and cybersecurity. He was firm that cybersecurity is not an IT concern but a matter of trust and business continuity patients trust the industry to deliver safe medicines, and partners trust it to protect intellectual property, trial data and manufacturing recipes.

Talent: quantity solved, capability the frontier

India produces the world’s largest pool of scientific and engineering talent, so the quantity question is settled. The real challenge is capability multi-disciplinary professionals who combine scientific depth with digital skills, business understanding and regulatory awareness. With the shelf life of technical skills shortening, he made the case that continuous learning is now a business necessity, not a personal choice: degrees get you hired; continuous learning determines how you sustain and grow.

Where AI is actually earning its keep

On AI, Dr. Basavaraju was pragmatic. Value is landing at the functional level today rather than enterprise-wide, with younger professionals adopting the tools fastest. Concrete wins he pointed to: prioritizing drug-discovery compounds so scientists synthesize fewer molecules, structuring and summarizing clinical-trial data, predictive maintenance and yield gains on the shop floor, and sharper demand forecasting across the supply chain. The recurring theme AI augments scientists and speeds decisions; it does not replace them.

On regulation, he noted that agencies such as the USFDA are raising expectations and upskilling, but the pace of innovation still runs ahead of them. A telling signal: a USFDA AI-assisted remote-audit pilot reported earlier this year, which he framed as a more opportunistic way to review a site than the traditional week-long inspection.

The takeaways

Asked to distill it, he offered three lines. What India gets genuinely right: execution at scale. What holds it back: innovation and original research. What global CEOs still get wrong: seeing India as a manufacturing destination when it is rapidly becoming a hub of innovation, digital transformation and strategic leadership.

Our thanks to Dr. Girish Basavaraju for a genuinely different conversation, and to everyone who joined live. The full recording is available on this page and on our YouTube channel ( https://www.youtube.com/@indiaautomationhub ) — questions are welcome in the comments, and our next session will be announced across our social handles.